The precision medicine-driven clinical trial will enroll patients in China with multi-organ, recurrent/refractory metastatic renal cell carcinoma based on expression of the Axl or Ror2 targets in tumor biopsy.
Axl and Ror2 targeted CAB-CAR-T cellular products to be tested in patients with refractory, metastatic kidney cancer |
| [08-January-2018] |
| SAN DIEGO, Jan. 8, 2018 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today that Shanghai Sinobioway Sunterra Biotechnology, a partner of F1 Oncology Inc., has received ethics committee approval of a clinical trial for two novel, conditionally active chimeric antigen receptor T cell (CAB-CAR-T) product candidates targeting Axl and Ror2 for the treatment of metastatic renal cell carcinoma. The precision medicine-driven clinical trial will enroll patients in China with multi-organ, recurrent/refractory metastatic renal cell carcinoma based on expression of the Axl or Ror2 targets in tumor biopsy. F1 Oncology, BioAtla’s partner in CAB technology applications for adoptive cellular therapies (ACTs), combines BioAtla’s CAB technology with F1 Oncology’s proprietary technologies with the goal of developing and commercializing CAB-CAR-T therapies for the treatment of solid tumor malignancies. CAB-CAR-T cell therapies are designed to be conditionally active only in the tumor microenvironment and may therefore help reduce potential adverse events associated with on-target, off-tumor effects of CAR-T therapies. In 2016 BioAtla granted F1 Oncology an exclusive worldwide license under patents and know-how controlled by BioAtla to discover, develop, manufacture and commercialize ACT preparations and treatments for cancer. The amended financial terms of this license to F1 Oncology include a mid-single digit royalty outside of China, Hong Kong, Macau and Taiwan (the Territory) and a low single-digit royalty within the Territory. BioAtla has a majority, non-controlling interest in the outstanding capital stock of F1 Oncology and has no funding or financial obligation. About Conditionally Active Biologics (CABs) Studies have shown that cancerous tumors create highly specific conditions at their site that are not present in normal tissue. These cancerous microenvironments are primarily a result of the well understood unique glycolytic metabolism associated with cancer cells, referred to as the Warburg Effect. CAB proteins are designed to deliver their therapeutic payload and/or recruit the immune response in specific and selected locations and conditions within the body and to be active only in the presence of a particular cellular microenvironment. In addition, the activation is designed to be reversible to repeatedly switch ‘on and off’ should the CAB move from a diseased to a normal cellular microenvironment and vice versa. CABs can be developed in a variety of formats including antibodies, antibody drug conjugates (ADCs), bi-specifics, chimeric antigen receptor T-cells (CAR-Ts) and combination therapies. About BioAtla, LLC Contact: Richard Waldron
View original content with multimedia:http://www.prnewswire.com/news-releases/clinical-trial-utilizing-bioatlas-conditionally-active-biologics-in-car-t-candidates-for-solid-tumors-to-be-initiated-in-china-300579025.html SOURCE BioAtla, LLC |
